Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
QEL-003
- Development stage
- Preclinical
- Lead developer
- Quell Therapeutics
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
01
Overview
QEL-003 is an autologous CAR-Treg cell therapy being co-developed by Quell Therapeutics and AstraZeneca for the treatment of Inflammatory Bowel Disease. This therapy utilizes the patient's own regulatory T cells (Tregs) which are engineered with a Chimeric Antigen Receptor (CAR) to modulate immune dysfunction. Quell Therapeutics is responsible for manufacturing and control support through early clinical studies. AstraZeneca exercised its option to license QEL-003 in June 2025, triggering a $10 million milestone payment to Quell, as part of a broader collaboration initiated in 2023 that includes potential milestones exceeding $2 billion.
Beyond the preview
Go deeper on QEL-003.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on QEL-003.